NCT02966821 is a Phase 2 clinical trial of Surufatinib in Biliary Tract Cancer, sponsored by Hutchison Medipharma Limited.

Who is sponsoring NCT02966821?

NCT02966821 is sponsored by Hutchison Medipharma Limited.

What drugs are being tested in NCT02966821?

Interventions in NCT02966821: Surufatinib.

What condition does NCT02966821 study?

NCT02966821 studies Biliary Tract Cancer.

Is NCT02966821 still recruiting?

NCT02966821 is currently completed. Last updated 27 February 2019.

Last reviewed 2019-02-27 · How we verify

NCT02966821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Completed Phase 2 Last updated 27 February 2019

What this trial tests

Phase 2 trial testing Surufatinib in Biliary Tract Cancer in 39 participants. Completed in 30 November 2018.

Timeline

3 January 2017

Primary endpoint
17 August 2018

30 November 2018

Quick facts

Lead sponsor	Hutchison Medipharma Limited
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	3 January 2017
Primary completion	17 August 2018
Estimated completion	30 November 2018
Sites	5 locations across China

Drugs / interventions tested

Surufatinib — full drug profile →

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Hutchison Medipharma Limited — full company profile →

Who can join

18 and older, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic biliary tract carcinoma

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Biliary tract cancers: current knowledge, clinical candidates and future challenges.
Tariq NU, McNamara MG, Valle JW. · · 2019 · cited 79× · PMID 31015767 · DOI 10.2147/cmar.s157092
Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Woods E, Le D, Jakka BK, Manne A. · · 2022 · cited 31× · PMID 35565266 · DOI 10.3390/cancers14092137
Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer.
Liu J, Lu J, Wu L, Zhang T, et al · · 2025 · cited 9× · PMID 38242529 · DOI 10.1016/j.jare.2024.01.013
Emerging Therapies in Management of Cholangiocarcinoma.
Speckart J, Rasmusen V, Talib Z, GnanaDev DA, et al · · 2024 · cited 8× · PMID 38339363 · DOI 10.3390/cancers16030613
Cholangiocarcinoma: the quest for a second-line systemic treatment.
Vienot A, Neuzillet C. · · 2019 · cited 7× · PMID 35117107 · DOI 10.21037/tcr.2018.10.05
Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature.
Zhu W, Wang W, Shi Y, Shen B, et al · · 2023 · cited 3× · PMID 37101053 · DOI 10.1007/s00428-023-03545-2
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.
Xue S, Jiang W, Ma J, Xu H, et al · · 2025 · PMID 40693603 · DOI 10.1097/cm9.0000000000003705

Verify or expand the search:

Other trials of Surufatinib

Trials testing the same drug.

NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors · Phase 2 · recruiting
NCT07086456 — Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal · Phase 2 · recruiting
NCT06531291 — Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Ne · Phase 2 · not yet recruiting

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other Hutchison Medipharma Limited trials

Trials by the same sponsor.

NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02966821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
Last refreshed: 27 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02966821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing